Table 3 Correlation between baseline levels of urinary eicosanoids and clinical outcomes
CDAI Day 0 | CDAI reduction (Day 0-Week 24) * | Remission at week 24 (CDAI ≤ 2.8)* | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2§ | Model 1 | Model 2§ | Model 1 | Model 2§ | |||||||
B | P value | B | P value | B | P value | B | P value | B | P value | B | P value | |
tPGEM1 | -0.06 | 0.186 | -0.06 | 0.240 | -0.01 | 0.281 | -0.02 | 0.394 | -0.01 | 0.114 | 0.02 | 0.147 |
tPGDM1 | 0.05 | 0.834 | 0.01 | 0.980 | 0.01 | 0.835 | 0.07 | 0.591 | -0.03 | 0.346 | 0.04 | 0.506 |
PGIM2 | 0.81 | 0.726 | 3.86 | 0.157 | 0.04 | 0.491 | 1.22 | 0.373 | 0.13 | 0.604 | -0.13 | 0.809 |
TXBM2 | 0.46 | 0.826 | 2.09 | 0.477 | 0.01 | 0.849 | 1.02 | 0.311 | -0.19 | 0.389 | 0.44 | 0.417 |
Total PGs1 | 0.04 | 0.274 | -0.04 | 0.307 | 0.01 | 0.363 | -0.01 | 0.515 | -0.01 | 0.125 | 0.01 | 0.165 |
12-HETE3# | 0.11 | 0.263 | 3.59 | 0.271 | -0.09 | 0.268 | -0.59 | 0.629 | -0.09 | 0.863 | 0.09 | 0.869 |
LTE43# | 0.03 | 0.785 | -0.78 | 0.777 | 0.01 | 0.912 | 2.04 | 0.255 | 0.21 | 0.733 | -0.18 | 0.783 |